17α-Ethynyl-5α-androstane-3α, 17β-diol Treatment of MNU-Induced Mammary Cancer in Rats
Figure 3
Tumor Incidence. Seven-week-old female Lewis rats were treated with a single IP injection of 50 mg/kg MNU. Tumors developed for 90 days, prior to treatment () for 28 days with (1) cyclodextrin vehicle daily, (2) 6.6 mg HE3235 daily, (3) 4 mg HE3235 daily, (4) 6.6 mg HE3235 daily + 1.5 mg docetaxel weekly, (5) 1.5 mg docetaxel weekly, (6) 2.5 mg anastrazole daily, and (7) 0.25 mg tamoxifen weekly. HE3235 as a monotherapy or in combination with docetaxel, was more effective at decreasing the number of tumors and rendering animals disease-free, than comparator therapies. (a) the effect of treatment on the average number of tumors per animal. * start versus end of treatment = .0008 (6.6 mg HE3235), .0007 (4 mg HE3235), and <.0001 (HE3235+Tax); § end of treatment versus end of study = .0003 (Tax), .0016 (Ana), <.0001 (Tam). (b) the percentage of rats in each group without palpable tumors. (there were no disease-free animals in the vehicle group, not plotted.). ** versus HE3235 + Tax, <.0001, ** versus HE3235 + Tax, .0405. Tax, docetaxel; Ana, anastrozole; Tam, tamoxifen.
